Scarica l'app Stockscreener
15.18
3.19%
-0.50
Dopo l'orario di chiusura:
15.22
0.04
+0.26%
Precedente Chiudi:
$15.68
Aprire:
$16.25
Volume 24 ore:
7.48M
Relative Volume:
2.97
Capitalizzazione di mercato:
$3.61B
Reddito:
$488.56M
Utile/perdita netta:
$209.45M
Rapporto P/E:
17.83
EPS:
0.8515
Flusso di cassa netto:
$40.61M
1 W Prestazione:
-6.99%
1M Prestazione:
-10.50%
6M Prestazione:
-11.23%
1 anno Prestazione:
-3.80%
Intervallo 1D:
$14.71
$16.60
Intervallo di 1 settimana:
$14.71
$16.60
Portata 52W:
$13.76
$25.67
Adma Biologics Inc Stock (ADMA) Company Profile
Nome
Adma Biologics Inc
Settore
Industria
Telefono
(201) 478-5552
Indirizzo
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
15.18 | 3.73B | 488.56M | 209.45M | 40.61M | 0.8515 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.13 | 122.71B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
770.79 | 82.91B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
771.53 | 50.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.24 | 43.42B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
322.37 | 38.98B | 4.98B | 69.60M | 525.67M | 0.5198 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-07-19 | Ripresa | Raymond James | Strong Buy |
| 2022-10-13 | Iniziato | Mizuho | Buy |
| 2021-11-11 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2021-11-09 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-04 | Iniziato | Jefferies | Buy |
| 2019-04-15 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-07 | Ripresa | H.C. Wainwright | Buy |
| 2017-12-11 | Reiterato | Maxim Group | Buy |
| 2017-11-14 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2017-01-23 | Aggiornamento | Maxim Group | Hold → Buy |
| 2016-08-01 | Downgrade | Maxim Group | Buy → Hold |
| 2016-07-25 | Reiterato | Maxim Group | Buy |
| 2015-05-13 | Reiterato | Maxim Group | Buy |
| 2014-12-08 | Iniziato | Oppenheimer | Outperform |
| 2014-12-01 | Reiterato | Maxim Group | Buy |
Mostra tutto
Adma Biologics Inc Borsa (ADMA) Ultime notizie
ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance - Finviz
Westfield Capital Management Co. LP Takes $74.87 Million Position in ADMA Biologics Inc $ADMA - MarketBeat
New ADMA Biologics CFO Takes Helm As Valuation Gap Draws Focus - Yahoo Finance
Decoding ADMA Biologics Inc (ADMA): A Strategic SWOT Insight - GuruFocus
ADMA Biologics Inc (ADMA) Q4 2025 Earnings Call Highlights: Stro - GuruFocus
ADMA Biologics Inc earnings beat by $0.03, revenue fell short of estimates - Investing.com
ADMA Biologics (ADMA) Reports Strong 2025 Results and Positive O - GuruFocus
ADMA Biologics Reports Strong Q4 2025 Earnings and Positive Outlook - Intellectia AI
ADMA Biologics Q4 2025 Earnings Call Transcript - MarketBeat
ADMA forecasts $635M revenue for 2026 as ASCENIV drives margin expansion and new supply deals extend growth runway - MSN
ADMA Biologics Q4 Earnings Call Highlights - Yahoo Finance
ADMA Biologics Says Brad Tade Is Retiring As Chief Financial Officer - TradingView
Earnings call transcript: ADMA Biologics reports strong Q4 2025 growth - Investing.com
ADMA Biologics (NASDAQ:ADMA) Issues Quarterly Earnings Results - MarketBeat
ADMA BIOLOGICS, INC. SEC 10-K Report - TradingView
(ADMA) ADMA Biologics Expects 2026 Revenue to Exceed $635M, vs. FactSet Est of $633.8M - marketscreener.com
Adma Biologics: Fourth Quarter Financial Overview - Bitget
ADMA Biologics Announces CFO Transition and Leadership Change - TipRanks
Adma Biologics: Q4 Earnings Snapshot - Barchart.com
ADMA Biologics CFO Brad Tade retires; Terry Kohler promoted to CFO - TradingView
ADMA Biologics, Inc. Announces Chief Financial Officer Changes - marketscreener.com
ADMA Biologics earnings up next: Can momentum match lofty targets? By Investing.com - Investing.com Canada
ADMA Biologics earnings up next: Can momentum match lofty targets? - Investing.com India
Aug Outlook: Is ADMA Biologics Inc attractive for institutional investorsGap Down & Weekly High Return Stock Opportunities - baoquankhu1.vn
Aug Outlook: Whats the beta of ADMA Biologics Inc stockMarket Activity Recap & Short-Term Swing Trade Alerts - baoquankhu1.vn
ADMA Biologics to Announce Q4 Earnings on February 25 - Intellectia AI
Preview: ADMA Biologics's Earnings - Benzinga
What To Expect From ADMA Biologics Inc (ADMA) Q4 2025 Earnings - GuruFocus
ADMA Biologics Inc (ADMA) Stock Analysis: A Biotech With A 59.42% Potential Upside - DirectorsTalk Interviews
ADMA Biologics (ADMA) to Release Quarterly Earnings on Monday - MarketBeat
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Aberdeen Group plc Increases Stock Holdings in ADMA Biologics Inc $ADMA - MarketBeat
ADMA Biologics CEO Sale And Options Activity Versus Valuation And Momentum - Yahoo Finance
ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 - Quiver Quantitative
Adam Grossman, president of Adma Biologics, sells $337,679 in shares By Investing.com - Investing.com South Africa
Adam Grossman, president of Adma Biologics, sells $337,679 in shares - Investing.com
(ADMA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
ADMA Biologics Inc (ADMA) Stock Analysis: Unlocking a 59.52% Upside in the Biotech Arena - DirectorsTalk Interviews
Public Sector Pension Investment Board Acquires 116,867 Shares of ADMA Biologics Inc $ADMA - MarketBeat
Assessing ADMA Biologics (ADMA) Valuation After Recent Share Price Rebound - Sahm
Market Leaders: Can ADMA Biologics Inc outperform in the next rallyJuly 2025 Analyst Calls & Risk Controlled Stock Alerts - baoquankhu1.vn
What are ADMA Biologics Inc.’s growth leversJuly 2025 Review & Community Trade Idea Sharing Platform - mfd.ru
Aug Movers: What is the cash position of REPXJuly 2025 Weekly Recap & Target Return Focused Picks - baoquankhu1.vn
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note - Nasdaq
Navellier & Associates Inc. Has $176,000 Stake in ADMA Biologics Inc $ADMA - MarketBeat
New York State Common Retirement Fund Decreases Stock Holdings in ADMA Biologics Inc $ADMA - MarketBeat
Principal Financial Group Inc. Cuts Stock Holdings in ADMA Biologics Inc $ADMA - MarketBeat
ADMA Biologics Inc (ADMA) Stock Analysis: Attractive 56.22% Upside Potential For Investors - DirectorsTalk Interviews
Renaissance Group LLC Has $7.57 Million Stock Holdings in ADMA Biologics Inc $ADMA - MarketBeat
(ADMA) Risk Channels and Responsive Allocation - Stock Traders Daily
Assessing ADMA Biologics (ADMA) Valuation After Growing Analyst Optimism On Earnings And Plasma Therapy Pipeline - Yahoo Finance
Adma Biologics Inc Azioni (ADMA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Adma Biologics Inc Azioni (ADMA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Grossman Adam S | President and CEO |
Feb 17 '26 |
Sale |
16.08 |
21,000 |
337,680 |
2,284,379 |
0.11%
0.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):